Patient Support Services Contact Us

Investors

Overview

Coherus is a late-stage biologics platform company focused on the global biosimilar market. Headquartered in the San Francisco Bay Area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team’s collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. Our commercialization partnerships include global pharmaceutical companies in Europe, Asia and Latin America.

Recent News
02/14/19
REDWOOD CITY, Calif. , Feb. 14, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that its fourth quarter and full year 2018 financial results will be released after market close on Thursday, February 28, 2019 . Starting at 4:30 p.m.
02/07/19
REDWOOD CITY, Calif. , Feb. 07, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that effective February 6, 2019 , the compensation committee of the company’s board of directors granted three new employees options to purchase an aggregate of 40,000 shares of the
01/25/19
Complaint alleges Amgen infringes three U.S. patents recently awarded to Coherus REDWOOD CITY, Calif. , Jan. 25, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), a commercial biosimilar company, today announced it has filed suit against Amgen in the United States District Court (
01/25/19
- The settlement affords U.S. market entry of December 15, 2023 - REDWOOD CITY, Calif. , Jan. 25, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), a commercial biosimilar company, today announced it has executed settlement agreements with AbbVie Inc.
Upcoming Events

Receive E-mail Alerts

Click here to receive e-mail alerts whenever Coherus Biosciences Inc posts new information to the site.

 

Copyright West LLC. Minimum 15 minutes delayed.